The best selections of Biotechnology and Farma by JPMorgan for the second half
The low performance of biopharmaceutical actions versus the widest market for a third consecutive year is an opportunity for investors,…
The low performance of biopharmaceutical actions versus the widest market for a third consecutive year is an opportunity for investors,…
Rafael Henrique | LIGHTROCKET | Getty images The actions of the main vaccine manufacturers fell on Monday after a key…
The trends may be turning in favor of biotech stocks in 2025 after several years of poor performance, but it…
Enthusiasm for Eli Lilly, the club's holding company, needs to be tempered, at least for now, as Wall Street grapples…